Teva Suit Built On 'Tottering Tower Of Conjecture,' FDA Says
Teva Pharmaceuticals' high-profile challenge to a new U.S. Food and Drug Administration policy on generic-drug exclusivity is wildly speculative and has virtually no chance of succeeding, the FDA told a D.C....To view the full article, register now.
Already a subscriber? Click here to view full article